ABIVAX Société Anonyme (NASDAQ:ABVX) Shares Gap Down – What’s Next?

ABIVAX Société Anonyme (NASDAQ:ABVX) shares gapped down before the market opened on Thursday . The stock had previously closed at $10.18, but opened at $9.78. ABIVAX Société Anonyme shares last traded at $9.70, with a volume of 911 shares trading hands.

Analyst Ratings Changes

Separately, Laidlaw assumed coverage on shares of ABIVAX Société Anonyme in a research note on Monday, July 29th. They set a “buy” rating and a $48.00 target price for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, ABIVAX Société Anonyme presently has an average rating of “Moderate Buy” and an average price target of $36.50.

ABIVAX Société Anonyme Stock Down 1.2 %

The business’s 50 day simple moving average is $10.69 and its 200 day simple moving average is $12.20.

Hedge Funds Weigh In On ABIVAX Société Anonyme

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in shares of ABIVAX Société Anonyme in the 1st quarter worth $81,000. Kennedy Capital Management LLC grew its stake in shares of ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after buying an additional 31,331 shares in the last quarter. Walleye Capital LLC grew its stake in shares of ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after buying an additional 80,807 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of ABIVAX Société Anonyme by 18.2% during the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after purchasing an additional 131,414 shares during the period. Finally, abrdn plc boosted its stake in shares of ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares during the period. 47.91% of the stock is owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.